Durvalumab plus chemo with RMT for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies a new treatment plan that combines RMT with durvalumab and chemotherapy in people with untreated advanced lung adenocarcinoma. It aims to improve outcomes by helping the immune system and fighting cancer cells together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung adenocarcinoma (confirmed by biopsy or cells) that is stage IIIB/C or stage IV and cannot be removed with surgery.
- Your tumor must NOT have certain gene changes (EGFR activating mutations, ALK, ROS1, or other listed targets like BRAF, RET, NTRK, or MET exon 14).
- You have at least one measurable tumor spot that can be tracked on scans.
- You must be able to provide stored, unused tumor tissue slides from the past (at least 10 unstained slides).
- Your body can handle treatment: good blood counts, liver/kidney function, and you’re well enough to do daily activities (ECOG 0–1).
- You can swallow pills/medicines and you understand the study and agree in writing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests durvalumab (an immunotherapy) together with focused, ablative radiation to treat metastatic small cell lung cancer. It may help shrink tumors and improve outcomes, especially when at least one tumor can be safely targeted with this radiation plan.
This phase 2 trial studies whether durvalumab given with consolidation radiotherapy can help people with extensive-stage small cell lung cancer that has only a few metastases. It builds on initial chemotherapy and immunotherapy response, then targets the chest and limited metastatic spots with radiation.
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This trial tests adding durvalumab (an immune therapy) to a radiation treatment plan for people with non-small cell lung cancer (NSCLC) who can’t safely have chemotherapy at the same time or surgery first. It aims to improve cancer control after radiation by helping the immune system recognize and fight the tumor.
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.